193 related articles for article (PubMed ID: 21119719)
1. Accelerating orphan drug development.
Coté TR; Xu K; Pariser AR
Nat Rev Drug Discov; 2010 Dec; 9(12):901-2. PubMed ID: 21119719
[TBL] [Abstract][Full Text] [Related]
2. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
[TBL] [Abstract][Full Text] [Related]
3. Drug labels: a flawed source of data for studying orphan drug approvals.
Kesselheim AS; Avorn J
Clin Pharmacol Ther; 2012 Dec; 92(6):694; author reply 695. PubMed ID: 23073207
[No Abstract] [Full Text] [Related]
4. Flexibility in the FDA approach to orphan drug development.
Hunter NL; Rao GR; Sherman RE
Nat Rev Drug Discov; 2017 Nov; 16(11):737-738. PubMed ID: 28860647
[No Abstract] [Full Text] [Related]
5. Clinical pharmacology as a cornerstone of orphan drug development.
Bashaw ED; Huang SM; Coté TR; Pariser AR; Garnett CE; Burckart G; Zhang L; Men AY; Le CD; Charlab R; Gobburu JV; Lesko LJ
Nat Rev Drug Discov; 2011 Oct; 10(11):795-6. PubMed ID: 22037026
[TBL] [Abstract][Full Text] [Related]
6. Prospects for rapid advances in the development of new medicines for special medical needs.
Milne CP
Clin Pharmacol Ther; 2014 Jan; 95(1):98-109. PubMed ID: 23917473
[TBL] [Abstract][Full Text] [Related]
7. A clinical pharmacology-regulatory perspective on the approval of drugs for rare diseases.
Bashaw ED
Clin Pharmacol Ther; 2016 Oct; 100(4):327-9. PubMed ID: 27417549
[TBL] [Abstract][Full Text] [Related]
8. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
Oo C; Rusch LM
J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
[No Abstract] [Full Text] [Related]
9. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
10. Accelerating access to treatments for rare diseases.
Dunoyer M
Nat Rev Drug Discov; 2011 Jun; 10(7):475-6. PubMed ID: 21701499
[TBL] [Abstract][Full Text] [Related]
11. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
Le TT
Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
[TBL] [Abstract][Full Text] [Related]
12. Accelerated approval dust begins to settle.
Mullard A
Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
[No Abstract] [Full Text] [Related]
13. FDA program could boost treatments for neglected diseases.
Traynor K
Am J Health Syst Pharm; 2008 Sep; 65(17):1595-6. PubMed ID: 18714098
[No Abstract] [Full Text] [Related]
14. Examining Manufacturing Readiness for Breakthrough Drug Development.
Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
[No Abstract] [Full Text] [Related]
15. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
Tambuyzer E
Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
[TBL] [Abstract][Full Text] [Related]
16. A human-on-a-chip approach to tackling rare diseases.
de Mello CPP; Rumsey J; Slaughter V; Hickman JJ
Drug Discov Today; 2019 Nov; 24(11):2139-2151. PubMed ID: 31412288
[TBL] [Abstract][Full Text] [Related]
17. Statistical considerations for rare diseases drug development.
Chow SC; Chang YW
J Biopharm Stat; 2019; 29(5):874-886. PubMed ID: 31454299
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis to guide orphan drug development.
Lesko LJ
Clin Pharmacol Ther; 2012 Aug; 92(2):258-61. PubMed ID: 22739138
[TBL] [Abstract][Full Text] [Related]
19. Botanicals as "new" drugs: US development.
Hoffman FA
Epilepsy Behav; 2015 Nov; 52(Pt B):338-43. PubMed ID: 26319115
[TBL] [Abstract][Full Text] [Related]
20. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE
Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
[No Abstract] [Full Text] [Related]
[Next] [New Search]
